Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06426368
Other study ID # ST2 in H.F patients
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date July 1, 2024
Est. completion date January 1, 2027

Study information

Verified date May 2024
Source Assiut University
Contact Dalia Hesham
Phone 01149936172
Email daliahesham1771993@gmail.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

1. The aim of this study was to explore the relationship between peripheral circulating serum soluble suppression of tumorigenicity-2 (sST2) levels and inflammatory biomarkers in patients with heart failure 2. Additive role of sST2 to NPs in of heart failure patients


Description:

Heart failure (HF), a complex and heterogeneous medical syndrome characterized by structural and functional cardiac abnormalities and hemodynamic disruptions, represents the end-stage manifestation of numerous cardiovascular disorders . HF is categorized into three groups based on the measurement of the left ventricular (LV) ejection fraction (LVEF) according to the European Society of Cardiology (ESC) Guidelines issued in 2021: HF with reduced ejection fraction (HFrEF, LVEF ≤ 40%), HF with mildly reduced ejection fraction (HFmrEF, LVEF 41-49%), and HF with preserved ejection fraction (HFpEF, LVEF ≥ 50%) . Quantifying concentrations of circulating biomarkers plays a major role in most cardiovascular (CV) diseases, including (HF) . An ideal biomarker in HF should be measured non-invasively and at low cost, highly sensitive to allow for the early detection of the disease . N-terminal pro-B-type natriuretic peptide (NT-proBNP) released by cardiac muscle tissue in response to abnormal volume load is an established indicator for the diagnosis and prognosis of HF . However, there are important limitations to natriuretic peptide (NP) testing in HF . Soluble suppression of tumorigenicity-2 (sST2) is the circulating form of the interleukin-33 membrane receptor released in response to inflammation, fibrosis in various organs, and myocardium stress . Soluble (s)ST2 has been proposed as a useful biomarker for heart failure (HF) patient management. Myocardial damage or mechanical stress stimulate sST2 release. ST2 competes with a membrane bound receptor (ST2 ligand, or ST2L) for interleukin-33 (IL-33) binding, inhibiting the effects induced by the ST2L/IL-33 interaction so that excessive sST2 may contribute to myocardial fibrosis and ventricular remodelling. So biomarkers such as NT-proBNP and sST2 could potentially be used as surrogates for clinical outcomes in patients with HF and may be useful in monitoring disease progression and assessing the response to therapy .


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 100
Est. completion date January 1, 2027
Est. primary completion date July 1, 2026
Accepts healthy volunteers
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - patients 18-80 years. - Both sexes will be included. - including signs and symptoms of HF (e.g., elevated jugular venous pressure and altered apical beat position), altered LVEF (< 40%; 40%-49%; = 50%) Exclusion Criteria: - Patients <18 years - Patients with documented evidence of cardiogenic shock . - Patients with Acute coronary syndrome within 30 days. - chronic kidney disease patients with glomerular filtration rate < 30 - Patients with interstitial pulmonary fibrosis .

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
ST2
ELISA used to detect levels of ST2 and BNP as inflammatory biomarkers in patients with heart failure

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Assiut University

References & Publications (1)

Purdy GE, Payne SM. The SHI-3 iron transport island of Shigella boydii 0-1392 carries the genes for aerobactin synthesis and transport. J Bacteriol. 2001 Jul;183(14):4176-82. doi: 10.1128/JB.183.14.4176-4182.2001. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary To evaluate if Soluble ST2 is strongly associated with measures of HF severity and poor outcome Study ST2 level in heart failure patients and correlate results with clinical data and other inflammatory biomarker Baseline
Primary Evaluation of BNP and ST2 could have a potential role in prognosis. Study value of BNP in prognosis and compare it with ST2 Baseline
Secondary • Clinical Impact and Treatment Decision Support Evaluate ST2 as a novel biomarker which provide risk stratification of patients with acute and chronic HF beyond BNPs Baseline
See also
  Status Clinical Trial Phase
Completed NCT03859466 - Safety and Efficacy of Cardiac Shockwave Therapy in Patients Undergoing Coronary Artery Bypass Grafting N/A
Completed NCT02571270 - 12-Week-Combined Physical Training In Heart Failure Patients N/A
Completed NCT03701854 - Physical Impairments in Heart Failure Patients With Pacemakers
Recruiting NCT04434716 - Monitoring and Self-management of Sleep Fatigue and Dyspnea N/A
Completed NCT04587947 - Influence of Sacubitril/Valsartan on Autonomic Cardiac Nervous System in Heart Failure Patients: an Exploratory Study N/A